Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Primary Central Nervous System Lymphoma
Condition: Primary Central Nervous System Lymphoma Interventions: Drug: ICP-022; Drug: Pemetrexed Sponsor: Henan Cancer Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials